Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies
Ministry of Health of the Republic of Croatia (MIZ Croatia)
Record ID 32018001143
Authors' objectives: This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. This Joint Assessment aims to compare the clinical effectiveness and safety of ustekinumab in the target patient populations with relevant comparators (according to the national requirements of the EUnetHTA partners, the relevant comparators are adalimumab, infliximab, golimumab, vedolizumab, tofacitinib).
Project Status: Completed
URL for project: https://eunethta.eu/ptja07-ustekinumab-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-uc-who-have-had-an-inadequate-response-with-lost-response-to-or-were-intoler/
Year Published: 2019
URL for published report: https://eunethta.eu/ptja07-ustekinumab-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-uc-who-have-had-an-inadequate-response-with-lost-response-to-or-were-intoler/
English language abstract: An English language summary is available
Publication Type: Rapid Review
- Colitis, Ulcerative
- Antibodies, Monoclonal, Humanized
- Anti-Inflammatory Agents
Organisation Name: European Network for Health Technology Assessment
Contact Email: firstname.lastname@example.org
Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.